Physician profile
Danielle Gates
NPI 1740832039
$3,590.73
in general payments reported to CMS, 2019-2025
24 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,352 · 2022: $547 · 2023: $445 · 2024: $1,010 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $616.68 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $511.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $342.82 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $271.21 | 2021-2023 | |
| Amgen INC. | $254.40 | 2021-2024 | Repatha |
| Pfizer INC. | $236.60 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $224.98 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $223.96 | 2021-2024 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.52 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $128.59 | 2024-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.98 | 2022-2025 | Lifevest |
| Esperion Therapeutics, INC. | $90.35 | 2021-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $81.34 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $77.73 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $49.86 | 2023-2024 | Inpefa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $41.14 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $34.70 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $31.57 | 2024 | Uptravi, Opsumit |
| Abbott Laboratories | $29.31 | 2023 | Jot Dx |
| Sanofi-Aventis U.S. LLC | $21.45 | 2022 | |
| Akcea Therapeutics, INC. | $19.73 | 2021 | |
| Lantheus Medical Imaging, INC. | $19.64 | 2025 | |
| Lilly USA, LLC | $19.40 | 2024 | Mounjaro |
| Impulse Dynamics (USA) INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.